MedeliX
Start asking

Methocarbamol

Methocarbamol Kwizda · ATC code M03BA03

Also known as: Metokarbamol · Brand names: Methocarbamol Kwizda, Methoca, Methocarbamol Al, Methocarbamol Aristo, Methocarbamol Hexal, Methocarbamol Micro Labs, Methocarbamol Neuraxpharm, Methocarbamol Stada, Ortoton, Atmeksi, Robaxin, Tanlor

Key facts
Active substance
Methocarbamol
Drug class
Muscle relaxant
ATC code
M03BA03
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Methocarbamol is a centrally acting muscle relaxant. Per the US prescribing information, it is used as an adjunct to rest and physical therapy for acute, painful musculoskeletal conditions.

What it is used for

  • Adjunct to rest, physical therapy and other measures for relief of discomfort in acute, painful musculoskeletal conditions
  • Its mode of action is not clearly identified and may relate to its sedative properties; it does not directly relax tense skeletal muscles

Dosing

  • 500 mg tablets (adults): initially 3 tablets 4 times daily, maintenance 2 tablets 4 times daily
  • 750 mg tablets (adults): initially 2 tablets 4 times daily, maintenance 1 tablet every 4 hours or 2 tablets 3 times daily
  • Six grams a day are recommended for the first 48 to 72 hours, up to 8 grams a day in severe conditions; thereafter usually about 4 grams a day

Contraindications

  • Hypersensitivity to methocarbamol or any tablet component

Important warnings

  • May have a general CNS depressant effect; caution with alcohol and other CNS depressants
  • May impair the ability to drive or operate machinery (drowsiness, dizziness)
  • Fetal and congenital abnormalities have been reported after in utero exposure

Side effects

  • Nervous system: drowsiness, dizziness or lightheadedness, sedation, confusion, amnesia, diplopia, nystagmus, incoordination, seizures
  • Cardiovascular: bradycardia, flushing, hypotension, syncope
  • Digestive: dyspepsia, nausea, vomiting, jaundice
  • Anaphylactic reaction, angioneurotic edema, fever, headache, rash, pruritus, urticaria, metallic taste, blurred vision, leukopenia

Interactions

  • Alcohol and other CNS depressants: combined effects
  • Pyridostigmine bromide: effect may be inhibited; caution in myasthenia gravis treated with anticholinesterase agents
  • May cause color interference in certain urine screening tests (5-HIAA, VMA)

Pregnancy and breastfeeding

  • Should not be used in women who are or may become pregnant, particularly in early pregnancy, unless potential benefits outweigh possible hazards

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • Methocarbamol KwizdaKwizda Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • MethocaPuren Pharma Gmbh & Co. Kg · 1 register entry
  • Methocarbamol AlAliud Pharma Gmbh · 1 register entry
  • Methocarbamol AristoAristo Pharma Gmbh (Art 57) · 1 register entry
  • Methocarbamol HexalHexal Ag · 1 register entry
  • Methocarbamol Micro LabsMicro Labs Gmbh · 1 register entry
  • Methocarbamol NeuraxpharmNeuraxpharm Arzneimittel Gmbh · 1 register entry
  • Methocarbamol StadaStadapharm Gmbh · 1 register entry
  • OrtotonRecordati Pharma Gmbh · 3 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

USA

  • AtmeksiRosemont Pharmaceuticals LLC · 1 register entry
  • RobaxinHikma Pharmaceuticals USA Inc. · 1 register entry
  • TanlorForte Bio-Pharma · 1 register entry

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 9 more European countries
Czechia
Dolirobax
France
Lumirelax, Methocarbamol Arrow, Methocarbamol Biogaran, Methocarbamol Micro Labs, Methocarbamol Venipharm
Hungary
Dolirobax Tabletta
Luxembourg
Methocarbamol Micro Labs
Malta
Rolaxifor
Poland
Methocarbamol Espefa
Portugal
Robaxisal, Zelaz
Slovakia
Dolirobax
Spain
Dolirobax, Molitrem, Robaxin

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Methocarbamol (Granules Pharmaceuticals Inc.) – Prescribing Information, 2026-07-07. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f0d3966-962d-fa7c-e053-2a91aa0a8e3c
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/
  5. Wikidata (CC0): ATC M03BA.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.